Studies have shown that active fund managers routinely underperform the S&P500 index*​

Standard BioTools Inc. (NASDAQ: LAB)

LAB Stock Predictions and Ratings

WSX Rating:
BUY
WSX Forecast (1yr):
7.70%
Analyst Rating:
HOLD
Analyst Forecast (1yr):
-40.80%

LAB Stock Analysis

LAB PE Ratio: 5.7

LAB PEG Ratio: Not Available

LAB Forward EPS Growth (12 month): 0.00%

LAB PS Ratio: 5.2

LAB PSG Ratio: 2.7

LAB Forward Revenue Growth (12 month): 1.90%

LAB Articles

No data was found